Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Natural Alternatives International, Inc. company was founded in 1980 and is headquartered in San Marcos, California. Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print media and the Internet distribution channels. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Intercell AG really wants give the pharmaceutical industry a shot in the arm. The Austrian company develops new vaccinations that aim to invoke strong immune system responses. It sells a travelers vaccine for Japanese encephalitis in areas of Europe, the Asia/Pacific region, and North America. Vaccine development candidates aim to fight staph infections, pandemic influenza, hepatitis C, and other viral and bacterial infections. The company also develops antibody (protein) therapies. Intercell has commercial licensing and co-development agreements with larger companies, including Novartis, Sanofi-Aventis, and Merck.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

Biogen Idec Inc. company was founded in 1985 and is based in Cambridge, Massachusetts. Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), crohn’s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.